Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

By Ying-Nan P. Chen, M. LaMarche, H. Chan, P. Fekkes, J. García-Fortanet, M. Acker, Brandon Antonakos, C. Chen, Zhouliang Chen, V. Cooke and 43 more. Nature, 2016

795 citations recorded by the source corpus.

Subfields: Education, Law, Political Science and International Relations

View Paper: https://www.semanticscholar.org/paper/92bf4dbfc5395ce39e7e930f7ae424ef373816e2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Alexey I. Nesvizhskii
2. S. Dhanasekaran
3. Michael A. Gillette
4. S. Vasaikar
5. F. Petralia
6. Steven A. Carr
7. B. Reva
8. Gad Getz

Citations in the corpus

• Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma (2020, background): “PTPN11/Shp2 inhibitors have shown great promise in preclinical trials (Chen et al., 2016) and targeted agents from multiple companies are now in clinical trials.”
• PROTAC targeted protein degraders: the past is prologue (2022, background): “nonreceptor type 11 (PTPN11; also known as SHP2) inhibitor SHP099 (reF.(230)), which stabilizes a closed conformation of SHP2 (intramolecular); and cyclosporin(231),”